Trial Profile

Clinical study of Envafolimab in chronic hepatitis B

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 08 Feb 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Envafolimab (Primary)
Indications Hepatitis B
Focus Adverse reactions

Most Recent Events

08 Feb 2022 Status changed from not stated to planning.
21 Jan 2022 New trial record
17 Jan 2022 According to an Ascletis media release, the company received Investigational New Drug (IND) application approval by U.S. Food and Drug Administration (FDA) for initiation of global development of ASC22 (Envafolimab)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com